{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T03:24:44Z","timestamp":1789529084817,"version":"build-2803163510"},"reference-count":15,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1016\/j.bbmt.2014.06.003","type":"journal-article","created":{"date-parts":[[2014,6,9]],"date-time":"2014-06-09T11:46:58Z","timestamp":1402314418000},"page":"1641-1645","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":46,"title":["Reduced-Intensity Conditioning Hematopoietic Cell Transplantation Is an Effective Treatment for Patients with\u00a0SLAM-Associated Protein Deficiency\/X-linked Lymphoproliferative Disease Type 1"],"prefix":"10.1016","volume":"20","author":[{"given":"Rebecca A.","family":"Marsh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack J.","family":"Bleesing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanmuganathan","family":"Chandrakasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael B.","family":"Jordan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stella M.","family":"Davies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra H.","family":"Filipovich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2014.06.003_bib1","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1038\/26683","article-title":"The X-linked lymphoproliferative-disease gene product SAP regulates signals induced through the co-receptor SLAM","volume":"395","author":"Sayos","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.bbmt.2014.06.003_bib2","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/2424","article-title":"Host response to EBV infection in X-linked lymphoproliferative disease results from mutations in an SH2-domain encoding gene","volume":"20","author":"Coffey","year":"1998","journal-title":"Nat Genet"},{"key":"10.1016\/j.bbmt.2014.06.003_bib3","doi-asserted-by":"crossref","first-page":"13765","DOI":"10.1073\/pnas.95.23.13765","article-title":"Inactivating mutations in an SH2 domain-encoding gene in X-linked lymphoproliferative syndrome","volume":"95","author":"Nichols","year":"1998","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.bbmt.2014.06.003_bib4","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1203\/00006450-199510000-00001","article-title":"X-linked lymphoproliferative disease: twenty-five years after the discovery","volume":"38","author":"Seemayer","year":"1995","journal-title":"Pediatr Res"},{"key":"10.1016\/j.bbmt.2014.06.003_bib5","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1182\/blood-2010-07-298372","article-title":"Clinical similarities and differences of patients with X-linked lymphoproliferative syndrome type 1 (XLP-1\/SAP deficiency) versus type 2 (XLP-2\/XIAP deficiency)","volume":"117","author":"Pachlopnik Schmid","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2014.06.003_bib6","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1111\/j.1399-3038.2012.01282.x","article-title":"Clinical features and outcome of X-linked lymphoproliferative syndrome type 1 (SAP deficiency) in Japan identified by the combination of flow cytometric assay and genetic analysis","volume":"23","author":"Kanegane","year":"2012","journal-title":"Pediatr Allergy Immunol"},{"key":"10.1016\/j.bbmt.2014.06.003_bib7","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1182\/blood-2010-06-284935","article-title":"X-linked lymphoproliferative disease due to SAP\/SH2D1A deficiency: a multicenter study on the manifestations, management and outcome of the disease","volume":"117","author":"Booth","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2014.06.003_bib8","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/sj.bmt.1705016","article-title":"Allogeneic stem cell transplantation in X-linked lymphoproliferative disease: two cases in one family and review of the literature","volume":"36","author":"Lankester","year":"2005","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2014.06.003_bib9","doi-asserted-by":"crossref","first-page":"5824","DOI":"10.1182\/blood-2010-04-282392","article-title":"Reduced-intensity conditioning significantly improves survival of patients with hemophagocytic lymphohistiocytosis undergoing allogeneic hematopoietic cell transplantation","volume":"116","author":"Marsh","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2014.06.003_bib10","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1182\/blood-2005-05-1819","article-title":"Stem cell transplantation with reduced-intensity conditioning for hemophagocytic lymphohistiocytosis","volume":"107","author":"Cooper","year":"2006","journal-title":"Blood"},{"issue":"Suppl. 2","key":"10.1016\/j.bbmt.2014.06.003_bib11","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1038\/bmt.2008.283","article-title":"The use of reduced-intensity stem cell transplantation in haemophagocytic lymphohistiocytosis and Langerhans cell histiocytosis","volume":"42","author":"Cooper","year":"2008","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2014.06.003_bib12","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1016\/j.bbmt.2013.09.001","article-title":"An intermediate alemtuzumab schedule reduces the incidence of mixed chimerism following reduced-intensity conditioning hematopoietic cell transplantation for hemophagocytic lymphohistiocytosis","volume":"19","author":"Marsh","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2014.06.003_bib13","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/sj.bmt.1704795","article-title":"A\u00a0novel reduced-intensity stem cell transplant regimen for nonmalignant disorders","volume":"35","author":"Shenoy","year":"2005","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2014.06.003_bib14","series-title":"Evaluation of chemotherapeutic agents","first-page":"196","article-title":"The clinical evaluation of chemotherapeutic agents in cancer","author":"Karnofsky","year":"1949"},{"key":"10.1016\/j.bbmt.2014.06.003_bib15","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1002\/1097-0142(19871001)60:7<1651::AID-CNCR2820600738>3.0.CO;2-J","article-title":"The measurement of performance in childhood cancer patients","volume":"60","author":"Lansky","year":"1987","journal-title":"Cancer"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879114003504?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879114003504?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T14:49:50Z","timestamp":1761058190000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879114003504"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10]]},"references-count":15,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["S1083879114003504"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2014.06.003","relation":{},"ISSN":["1083-8791"],"issn-type":[{"value":"1083-8791","type":"print"}],"subject":[],"published":{"date-parts":[[2014,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reduced-Intensity Conditioning Hematopoietic Cell Transplantation Is an Effective Treatment for Patients with\u00a0SLAM-Associated Protein Deficiency\/X-linked Lymphoproliferative Disease Type 1","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2014.06.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}